USDA-NIFA SBIR Phase II John (PI) $649,999.76
Broadly Protective porcine Streptcoccus suis vaccines.  

National Institutes of Health – National Cancer Institute John PI $393,833.00
A Simple at-home test for rapid and accurate screening for Hepatitis C Virus (HCV) exposure: Small Business Innovation Research contract Phase I

PathoVacs secures STTR Phase II funding (~USD 1,000,000) from the Department of Defense (DoD) - Center for Biological Defense (CBD) for development of novel lateral flow-based assays for rapid diagnosis of early acute infections caused by Biothreat agents.

PathoVacs secures STTR Phase I funding (~USD 150,000) from the Department of Defense (DoD)  - Center for Biological Defense for the proposal "Circulating Diagnostic Markers of Infectious Disease." The Company will utilize  proprietary functional proteomics tools to identify pathogen-biomarkers for development of novel assays for diagnosis of infections by biothreat agents on the same day of / few days after infection. 

PathoVacs wins competitive USDA SBIR Phase I grant funding (~USD 100,000) for the project "Broadly protective Streptococcus suis swine vaccines." The Company will apply its patented protein antigen discovery platform to define vaccine candidates, and evaluate an experimental vaccine in new born pigs. 

PathoVacs and collabortors, PK Biosciences and the Nanovaccine Institute - Iowa State University, secure $50,000 Phase I research funding from the Iowa State Unversity (ISU) - Reagents Innovation Fund for development of new diagnostics and novel nanomedicines for Alzheimer's Disease.

PathoVacs and research partners, awarded $10,000 by the ISU Nanovaccines Presidential Initiative for Interdisciplinary research for studies toward development of a diagnostic assay for Parkinson's Disease. PathoVacs' efforts will add to those of collabortors, PK Biosciences and the Nanovaccine Institute - Iowa State University, for development of an enzyme immunoassay for early accurate diagnosis of Parkinson's Disease. 

PathoVacs and research collaborators, PK Biosciences, and the Nanovaccine Institute - Iowa State University awarded Phase II funding of $50,000 by the ISU Reagents Innovation Fund for "Evaluation of alpha-Synuclein immunotherapeutics in animal models of Parkinson's Disease."  

PathoVacs and research partners,  Iowa-based PK Biosciences and the Nanovaccine Institute - Iowa State University, awarded $50,000 Phase I grant by the ISU Reagents Innovation Fund for "Evaluation of alpha-Synuclein immunotherapeutics in animal models of Parkinson's Disease."